Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2112171
Abstract: ABSTRACT Background FVIII replacement is standard treatment for hemophilia A without inhibitors, but non-factor therapies, such as emicizumab, are changing the treatment landscape. We explore the ramifications of switching treatment. Methods Pharmacy database data (July… read more here.
Keywords: alfa pegol; rurioctocog alfa; pegol emicizumab;